Format

Send to

Choose Destination
Expert Opin Drug Saf. 2014 Sep;13(9):1175-85. doi: 10.1517/14740338.2014.937421.

Calcium supplementation in chronic kidney disease.

Author information

1
University of Chicago, Nephrology , 5841 S Maryland Avenue, Chicago, IL, 60637 , USA eworcest@uchicago.edu.

Abstract

INTRODUCTION:

There is high prevalence of calcium supplementation in the general population and some recent data suggest that this may increase the risk of vascular calcification. Calcium-based binders have been a standard treatment for hyperphosphatemia in patients with chronic kidney disease (CKD). Though as effective as phosphate binders, they provide a source of substantial calcium intake.

AREAS COVERED:

In addition to the balance studies recently completed to assess the implications of calcium loading in CKD, we also review observational studies and clinical trials involving calcium-based binders. Clinically significant endpoints such as vascular calcification, mortality and bone morphology were evaluated. The existing data are concerning for the role of calcium supplementation and calcium binder use in patients with renal compromise.

EXPERT OPINION:

There are few guidelines on advised calcium intake in patients with renal failure; however, on the basis of existing data, it may be safer to have the upper limit of calcium intake (including that of supplementation/binder use) up to 1 g. The old Kidney Disease Outcomes Quality Initiative suggestion of limiting the calcium intake to 2 g may need to be reconsidered.

KEYWORDS:

calcium acetate; calcium binders; calcium carbonate; calcium supplements; cardiovascular disease; chronic kidney disease; end-stage renal disease; lanthanum salts; milk alkali syndrome; renal osteodystrophy; sevelamer; vascular calcification

PMID:
25134623
DOI:
10.1517/14740338.2014.937421
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center